Sino Biological Recombinant Omicron BA5 and BA4 Antigens

Court Reconfirms Judgment in IGEN Suit Against Roche

IGEN International, Inc. (Nasdaq: IGEN) announced today that the U.S. District Court for the District of Maryland reaffirmed its final order of judgment in IGEN's case against Roche Diagnostics, a division of F. Hoffmann-La Roche (OTC Bulletin Board: RHHBY). The judgment, which was entered on February 15, 2002, awards IGEN $505 million in damages; confirms the Company's right to terminate the license agreement; and directs and commands Roche to grant to IGEN for use in its retained fields a license to improvements developed by Roche under the agreement, including Roche's Elecsys(R) diagnostics product line.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : IGEN International, Inc. View archived contact details

Posted on April 15, 2002